Yes, catalysts can be designed to improve the efficacy of immunotherapies. Nanozymes, which are nanomaterials with enzyme-like properties, can be employed to modulate the immune response. For example, they can be used to enhance the presentation of tumor antigens, thereby improving the effectiveness of cancer vaccines. Additionally, catalysts can be used to generate reactive oxygen species (ROS) that selectively kill cancer cells and activate immune cells.
